CHICAGO, USA—For patients with advanced non-small cell lung cancer harboring the rare exon-20 gene insertion,first-line treatment with the targeted drug sunvozertinib monotherapy brought statistically significant anti-tumor efficacy when compared with chemotherapy in the phase three WU-KONG28 study reported to the 2026 Annual Meeting of the American Society of Clinical Oncology by John V Heymach MD PhD, Professor and Chair of Thoracic and Head and Neck Medical Oncology, at the University of Texas MD Anderson Cancer Center, in Houston. After hearing Dr. Heymach’s talk, Audio Journal of Oncology reporter Peter Goodwin caught up with ASCO commentator David R Spigel MD, President and Chief Medical Officer at the Sarah Cannon Research Institute in Nashville, Tennessee. (An interview with David R Spigel MD, President & Chief Medical Officer, Sarah Cannon Research Institute, Nashville, Tennessee, US)

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related